U.S. markets open in 3 hours 51 minutes
  • S&P Futures

    3,856.50
    +37.25 (+0.98%)
     
  • Dow Futures

    31,959.00
    +183.00 (+0.58%)
     
  • Nasdaq Futures

    12,541.50
    +244.25 (+1.99%)
     
  • Russell 2000 Futures

    2,235.10
    +34.30 (+1.56%)
     
  • Crude Oil

    65.79
    +0.74 (+1.14%)
     
  • Gold

    1,699.90
    +21.90 (+1.31%)
     
  • Silver

    25.76
    +0.50 (+1.96%)
     
  • EUR/USD

    1.1910
    +0.0058 (+0.49%)
     
  • 10-Yr Bond

    1.5960
    0.0000 (0.00%)
     
  • Vix

    24.71
    +0.05 (+0.20%)
     
  • GBP/USD

    1.3868
    +0.0046 (+0.33%)
     
  • USD/JPY

    108.7510
    -0.1500 (-0.14%)
     
  • BTC-USD

    54,018.68
    +4,382.50 (+8.83%)
     
  • CMC Crypto 200

    1,090.89
    +66.68 (+6.51%)
     
  • FTSE 100

    6,748.24
    +29.11 (+0.43%)
     
  • Nikkei 225

    29,027.94
    +284.69 (+0.99%)
     

Outlook on the Trispecific Antibodies Global Market to 2024 - Featuring AbbVie, Affimed and Biotheus Among Others

Research and Markets
·6 min read

Dublin, Dec. 10, 2020 (GLOBE NEWSWIRE) -- The "Global Trispecific Antibodies Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering.

Trispecific cancer antibody therapy market at an early phase of development has crossed a long path to get recognized and appreciated as one of the most innovative and important breakthrough and achievement ever done in the complete cancer therapeutics sector. The development of antibody capable of targeting three different targets with the help of recombinant biotechnology is leading to the further explication of the market that monoclonal and bispecific antibodies were once performing at a very accelerated rate. Overall scientific information about the antibody targeting and how increasing the number of targeting molecules can increase the efficacy of the treatment triggered the researchers to develop a market that is inclined towards more specificity and eventually a steady decline in the global mortality rate due to cancer.

Trispecific cancer antibody therapy involves innovative approach of targeting three different epitopes present on the cancer cells which has apparently led to the acceptance of the therapy at clinical level for further evaluation. The unique mechanism of action of the therapy is also estimated to follow the path which will be driven by robust sales of the future drugs under the therapy. Some of the driving parameters that are associated with the overall market are: increase in the number of cancer cases, increase in cancer mortality rate, increased awareness of the antibody therapy applications and huge impact of the overall immunotherapy on the cancer patients.

The current details of the therapy at clinical level is reflecting the true performance where the therapy is anticipated to witness a remarkable growth with respect to revenue and size as the number of clinical research studies, investments and strong clinical base are coupled with the therapy from the starting. As per analysis conducted, it is estimated that the potential applications of trispecific cancer antibody therapy is bound to sweep away the market trends and opportunities of all the other traditional therapies, once the therapy gets accepted for commercial use by the patients.

The global trispecific cancer antibody therapy market is believed to be growing with novel innovative trends and opportunities as assessed for other important immunotherapies due to the presence of latest methodologies in the industry. The applications range within the therapy is also believed to get enhanced through the means of extensive research and development environment developed in course of time for therapies such as trispecific cancer antibody therapy. The therapy from the starting is associated with strategic alliances which are leading the therapy towards more specificity towards different varieties of cancers such as multiple myeloma, breast cancer, non-small cell lung cancer and many more. It is estimated that the therapy with the aid of growing tons of trends and opportunities will significantly grow and observe a speedy expansion in the next few years.

Global Trispecific Antibodies Market Opportunity & Clinical Trials Insight 2024 Report Highlights:

  • Commutative Market Opportunity During Initial 5 years of Commercialization: > US$ 2 Billion

  • Trispecific Antibodies In Clinical Trials: > 8 Antibodies

  • Highest Phase of Development: Phase I/II

  • Cancer Dominating Trispecific Antibodies Trials: > 5 Antibodies

  • Numab Therapeutics Dominating the Trispecific Development Pipeline

  • Prevention & Second Line Therapy Key Focus of Development of Trispecific Antibodies

Key Topics Covered:

1. Introduction to Global Trispecific Cancer Antibody Drug Market
1.1 Trispecific Cancer Antibody Mechanism of Action Against Cancer Cells
1.2 History of the Development of Trispecific Cancer Antibody Drug Development

2. Cancer Cases Engaging More Potential Trispecific Cancer Research Studies at Clinical Level
2.1 Trispecific Cancer Antibody Drug Therapy Market Beneficial for all Cancer Types
2.2 Potential Trispecific Cancer Antibody Therapy for Non-Small Cell Lung Cancer
2.3 Potential Trispecific Cancer Antibody Drug Therapy for the Treatment of Breast Cancer
2.4 Potential Trispecific Cancer Antibody Therapy Market for Prostate Cancer
2.5 Potential Trispecific Cancer Antibody Therapy Market for Rest of the Cancer Types
2.6 Trispecific Cancer Antibody Drug Immunotherapy Market as a Saviour for Increasing Prevalence of Cancer Cases
2.7 Trispecific Antibody Immunotherapy Market Clinical Experience

3. Clinical Insights for Current Trispecific Cancer Antibody Drug Therapy Market
3.1 Importance of Clinical Research Studies for the Overall Development of Trispecific Cancer Antibody Drug Therapy Market
3.2 Research Clinical Insights for Trispecific Cancer Antibody Drug Therapy against Multiple Myeloma

4. Trispecific Cancer Antibody Drug Therapy Market Overcoming the Challenges for Monoclonal Antibody & Bispecific Antibody Drug Market
4.1 Trispecific Cancer Antibody Drug Therapy Market an Enhanced Version of Monoclonal Antibody Therapy Market
4.1.1 Trispecific Cancer Antibody Drug Therapy Vs. General Monoclonal Antibody Drug Class
4.1.2 Construction Benefits of Using Trispecific Cancer Antibody Drug Therapy Over Monoclonal Antibodies
4.2 Trispecific Cancer Antibody Drug Therapy in Overcoming Bispecific Cancer Antibody Drug Therapy Challenges

5. Tri-Specific Natural Killer Cell Nanoengagers to Address Cancer Therapeutic Indication

6. Forging Novel Pathways for Improving Research & Development Sector for Cancer by Trispecific Cancer Antibody Therapy
6.1 Trispecific Cancer Antibody Drug Therapy Market Research & Development Sector Promoting Current Cancer Therapy Market
6.2 Novel Trispecific Cancer Antibody Therapy Drugs to Boost Chemotherapy Cancer Market
6.3 Novel Trispecific Cancer Antibody Drug Market Boosting the Future Radiation Therapy Market
6.4 Novel Trispecific Cancer Antibody Drug Market Boosting Other Available Cancer Therapies Market

7. Global Market Implications for Ongoing Research Studies & Collaborations for Trispecific Cancer Antibody Drug Market
7.1 Numab & Vasella Therapeutics to Collaborate for PD-L1x4-1BBxHSA Trispecific ND021 Candidate in the Cancer Patients
7.2 GTB-3550 Trispecific Recombinant Fusion Protein Development by GT Biopharma
7.3 Sanofi to Target Bi-specifcic & Multi-Specific Antibodies for Overall Development of Cancer Pharmaceutical Industry
7.4 Sunshine Pharmaceuticals & Numab Therapeutics to Undergo Partnership for the Development of Multi-Specific Cancer Antibody Drugs for Cancer Patients
7.5 SAR 441236 Trispecific Cancer Antibody Drug Development by Brigham Health Hospital
7.6 Numab Therapeutics Evaluation of NM21-1480 Trispecific Cancer Antibody in the Solid Cancer Patients

8. Global Trispecific Antibodies Clinical Pipeline Overview
8.1 By Country
8.2 By Indication
8.3 By Organization
8.4 By Patient Segment

9. Global Trispecific Antibodies Pipeline Clinical Insight By Company, Indication & Phase
9.1 Reserach
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II

10. Insight for Driving Factors & Challenges for the Trispecific Cancer Antibody Drug Market
10.1 Driving Parameters for Trispecific Cancer Antibody Drug Market
10.2 Challenge Observed for the Current Trispecific Cancer Antibody Drug Therapy Market

11. Future Directions for Trispecific Cancer Antibody Drug Therapy Market at Global Level

12. Competitive Landscape
12.1 AbbVie
12.2 Affimed
12.3 Biotheus
12.4 Harpoon Therapeutics
12.5 Macrogenics
12.6 Numab
12.7 Sanofi
12.8 Sichuan Baili Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/r/51pqsx

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900